Therapy News and Research

RSS

Multiple Epo doses with hypothermia offers neonate neuroprotection

Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.

1 Oct 2012

CBT ‘has no impact’ on juvenile fibromyalgia physical activity

Cognitive behavior therapy is not associated with increased physical activity levels in adolescents with juvenile fibromyalgia, research shows.

1 Oct 2012

Autoimmune disease myasthenia gravis halted in mice

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response the disorder triggers in the body.

1 Oct 2012

Clinical need, effectiveness, fairness should drive drugs allocation

A policy that is transparent, fair to patients and healthcare providers, and is based on clinical need is an ethically justifiable approach to rationing drugs that are in critically short supply, report researchers.

1 Oct 2012

Novel target identified for fragile X-linked autism

Researchers have elucidated a novel mechanism through which fragile X syndrome may contribute to behavioural symptoms of autism and identified a potential therapeutic target.

1 Oct 2012

Stenting advised for basilar tip aneurysm intervention

Stent-assisted coiling may be the best treatment option for basilar tip aneurysms, say US researchers.

1 Oct 2012

Cholesterol has repercussions for recovering heroin addicts

Cholesterol levels may be negatively associated with heroin craving in patients on methadone maintenance therapy, researchers suggest.

1 Oct 2012

BD family history risk factor for recurrent episodes in MDD

A family history of bipolar disorder increases the likelihood of recurrent episodes of hypomania or mania in individuals with prior major depressive disorder, suggest findings published in Bipolar Disorders.

1 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Most people completely unaware of aphasia

Most people are completely unaware of one of stroke's most common, debilitating but invisible impairments, according to the first awareness survey of its kind in Canada released today at the Canadian Stroke Congress.

1 Oct 2012

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

Home delivery of stroke rehabilitation improves care, eliminates waiting lists and saves costs

Home delivery of stroke rehabilitation improves care, eliminates waiting lists for treatment and saves hundreds of thousands of dollars annually in hospital costs, according to a quality improvement project presented today at the Canadian Stroke Congress.

1 Oct 2012

Administering immunotherapy for three years can reduce allergies, asthma in children

When children suffer from dust mite induced allergies and asthma, finding relief can seem impossible. While there isn't a complete cure for childhood respiratory allergies, researchers have found that long term control of allergic asthma can occur after only three years of allergy shots.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Rehabilitation robots help identify and customize post-stroke therapy

When it comes to stroke rehabilitation, it takes a dedicated team to help a person regain as much independence as possible: physicians, nurses, physiotherapists, occupational therapists, speech-language pathologists, recreation therapists, caregivers and others. Now, a University of Calgary research team has added a robot to help identify and customize post-stroke therapy.

1 Oct 2012